Islet autoantibody positivity in overweight and obese adults with type 2 diabetes

References

• Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab. 2009;94:4635–4644.
   PubMed Web of Science ®Google Scholar
• Turner R, Stratton I, Horton V, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet. 1997;350:1288–1293.
   PubMed Web of Science ®Google Scholar
• Davis TM, Wright AD, Mehta ZM, et al. Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia. 2005;48:695–702.
   PubMed Web of Science ®Google Scholar
• Zinman B, Kahn SE, Haffner SM, et al. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. Diabetes. 2004;53:3193–3200.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Xiang Y, Ji L, et al. Frequency, immunogenetics, and clinical characteristics of latent autoimmune diabetes in China (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study. Diabetes. 2013;62:543–550.
   PubMed Web of Science ®Google Scholar
• Hawa MI, Buchan AP, Ola T, et al. LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes. Dia Care. 2014;37:1643–1649.
   PubMed Web of Science ®Google Scholar
• Maddaloni E, Lessan N, Al Tikriti A, et al. Latent autoimmune diabetes in adults in the United Arab Emirates: clinical features and factors related to insulin-requirement. PLoS One. 2015;10:e0131837.
   PubMed Web of Science ®Google Scholar
• Trabucchi A, Faccinetti NI, Guerra LL, et al. Detection and characterization of ZnT8 autoantibodies could help to screen latent autoimmune diabetes in adult-onset patients with type 2 phenotype. Autoimmunity. 2012;45:137–142.
   PubMed Web of Science ®Google Scholar
• van Deutekom AW, Heine RJ, Simsek S. The islet autoantibody titres: their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus. Diabetic Med. 2008;25:117–125.
   PubMed Web of Science ®Google Scholar
• Desai M, Cull CA, Horton VA, et al. GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77. Diabetologia. 2007;50:2052–2060.
   PubMed Web of Science ®Google Scholar
• Davies H, Brophy S, Fielding A, et al. Latent autoimmune diabetes in adults (LADA) in South Wales: incidence and characterization. Diabet Med. 2008;25:1354–1357.
   PubMed Web of Science ®Google Scholar
• Andersen CD, Bennet L, Nystrom L, et al. Worse glycaemic control in LADA patients than in those with type 2 diabetes, despite a longer time on insulin therapy. Diabetologia. 2013;56:252–258.
   PubMedGoogle Scholar
• Olsson L, Grill V, Midthjell K, et al. Mortality in adult-onset autoimmune diabetes is associated with poor glycemic control results from the HUNT study. Diabetes Care. 2013;36:3971–3978.
   PubMed Web of Science ®Google Scholar
• Maldonado M, Hampe CS, Gaur LK, et al. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. J Clin Endocrinol Metab. 2003;88:5090–5098.
   PubMed Web of Science ®Google Scholar
• Balasubramanyam A, Garza G, Rodriguez L, et al. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care. 2006;29:2575–2579.
   PubMed Web of Science ®Google Scholar
• Littorin B, Sundkvist G, Hagopian W, et al. Islet cell and glutamic acid decarboxylase antibodies present at diagnosis of diabetes predict the need for insulin treatment - a cohort study in young adults whose disease was initially labeled as type 2 or unclassifiable diabetes. Diabetes Care. 1999;22:409–412.
   PubMed Web of Science ®Google Scholar
• UKPDS Study Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia. 1991;34:877–890.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 4. Lifestyle management: standards of medical care in diabetes. Diabetes Care. 2018;41:S38–S50.
   PubMed Web of Science ®Google Scholar
• Ryan DH, Espeland MA, Foster GD, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003;24:610–628.
   PubMedGoogle Scholar
• The Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–154.
   PubMed Web of Science ®Google Scholar
• The Look AHEAD Research Group, Wadden TA, West DS, et al. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring). 2006;14:737–752.
   PubMed Web of Science ®Google Scholar
• Wesche-Thobaben JA. The development and description of the comparison group in the Look AHEAD trial. Clin Trials. 2011;8:320–329.
   PubMed Web of Science ®Google Scholar
• Bottazzo GF, Bosi E, Cull CA, et al. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia. 2005;48:703–708.
   PubMed Web of Science ®Google Scholar
• Torn C, Landin-Olsson M, Lernmark A, et al. Combinations of beta cell specific autoantibodies at diagnosis of diabetes in young adults reflects different courses of beta cell damage. Autoimmunity. 2001;33:115–120.
   PubMed Web of Science ®Google Scholar
• Bonifacio E, Yu L, Williams AK, et al. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab. 2010;95:3360–3367.
   PubMed Web of Science ®Google Scholar
• Yu L, Boulware DC, Beam CA, et al. Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care. 2012;35:1213–1218.
   PubMed Web of Science ®Google Scholar
• Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A. 2007;104:17040–17045.
   PubMed Web of Science ®Google Scholar
• Schlosser M, Mueller PW, Achenbach P, et al. Diabetes antibody standardization program: first evaluation of assays for autoantibodies to IA-2beta. Diabetes Care. 2011;34:24102.
   Google Scholar
• Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–2497.
   PubMed Web of Science ®Google Scholar
• Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191–2192.
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27:1487–1495.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Revers RR, Kolterman OG, et al. Modulation of insulin secretion by insulin and glucose in type II diabetes mellitus. J Clin Endocrinol Metab. 1985;60:559–568.
   PubMed Web of Science ®Google Scholar
• Buzzetti R, Spoletini M, Zampetti S, et al. Tyrosine phosphatase-related islet antigen 2(256-760) autoantibodies, the only marker of islet autoimmunity that increases by increasing the degree of BMI in obese subjects with type 2 diabetes. Diabetes Care. 2015;38:513–520.
   PubMed Web of Science ®Google Scholar
• Juneja R, Hirsch IB, Naik RG, et al. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism. 2001;50:1008–1013.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S13–S27.
   PubMed Web of Science ®Google Scholar
• Shields BM, Peters JL, Cooper C, et al. Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open. 2015;5:e009088.
   PubMed Web of Science ®Google Scholar
• Pilla SJ, Maruthur NM, Schweitzer MA, et al. The role of laboratory testing in differentiating type 1 diabetes from type 2 diabetes in patients undergoing bariatric surgery. Obes Surg. 2018;28:25–30.
   PubMed Web of Science ®Google Scholar
• Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol. 2018;6:361–369.
   PubMed Web of Science ®Google Scholar
• Versini M, Jeandel PY, Rosenthal E, et al. Obesity in autoimmune diseases: not a passive bystander. Autoimmun Rev. 2014;13:981–1000.
   PubMed Web of Science ®Google Scholar
• Tiberti C, Zampetti S, Capoccia D, et al. Evidence of diabetes-specific autoimmunity in obese subjects with normal glucose tolerance. Diabetes Metab Res Rev. 2018;34:e3055.
   PubMed Web of Science ®Google Scholar
• Bansal N, Hampe CS, Rodriguez L, et al. DPD epitope-specific glutamic acid decarboxylase (GAD)65 autoantibodies in children with type 1 diabetes. Diabet Med. 2017;34:641–646.
   PubMed Web of Science ®Google Scholar